To find early predictors for poor neurodevelopmental outcome after neonatal group B streptococcal meningitis.
Methods
We retrospectively analyzed clinical characteristics of 23 patients with neonatal group B streptococcal meningitis and their neurodevelopmental outcome at 18 months. Available group B Streptococcus strains were serotyped and their genomes characterized.
Results
We found several differences between patients with early- (n = 5) and late-onset (n = 18) disease. Nine children had neurologic abnormalities at 18 months and 4 had epilepsy, all of them after late-onset disease. Most important risk factors for poor outcome were impaired consciousness at admission, hemodynamic instability, seizures, or abnormal electroencephalogram during the acute illness and abnormal neurologic and ophthalmologic examination at the end of treatment, whereas abnormalities in laboratory and imaging studies were not predictive. Hypervirulent serotype III, multilocus sequence type 17 group B Streptococcus was the predominant pathogen.
Conclusions
Neurodevelopmental impairment after neonatal group B streptococcal meningitis is likelier in those with clinical and neurophysiological features indicating worse disease severity.
BakerCJ. The spectrum of perinatal group B streptococcal disease. Vaccine. 2013;31(Suppl 4):D3-D6.
2.
EdwardsMSNizetVBakerCJ. Group B streptococcal infections. In: RemingtonJSKleinJOWilsonCB, et al, eds. Infectious Diseases of the Fetus and Newborn Infant. 7th ed. Philadelphia, PA: Elsevier Saunders; 2011:419-469.
3.
NizetVKleinJO. Bacterial sepsis and meningitis. In: RemingtonJSKleinJOWilsonCB, et al, eds. Infectious Diseases of the fetus and Newborn Infant. 7th ed. Philadelphia, PA: Elsevier Saunders; 2011:222-275.
4.
Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement—recommendations for the prevention of perinatal group B streptococcal (GBS) disease. Pediatrics. 2011;128(3):611-616.
5.
OhlssonAShahVS. Intrapartum antibiotics for known maternal group B streptococcal colonization. Cochrane Database Syst Rev. 2014;6:CD007467.
6.
BerardiARossiCLugliL, et al.Group B Streptococcus late-onset disease: 2003-2010. Pediatrics. 2013;131(2):e361-e368.
7.
BerardiARossiCGuidottiI, et al.Group B Streptococcus late-onset disease and milk transmission. Acta Paediatr. 2013;102(3):e95.
8.
EdmondKMKortsalioudakiCScottS, et al.Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379(9815):547-556.
9.
LeventFBakerCJRenchMAEdwardsMS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J. 2010;29(11):1009-1012.
10.
Kohli-LynchMRussellNJSealeAC, et al.Neurodevelopmental impairment in children after group B streptococcal disease worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65:S190-S199.
11.
ThigpenMWhitneyCMessonnierN, et al.Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364(21):2016-2025.
12.
OkikeIJohnsonAHendersonK, et al.Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis. 2014;59(10):E150-E157.
13.
MorrisseySMNielsenMRyanL, et al.Group B streptococcal PCR testing in comparison to culture for diagnosis of late onset bacteraemia and meningitis in infants aged 7-90 days: a multi-centre diagnostic accuracy study. Eur J Clin Microbiol Infect Dis. 2017;36(7):1317-1324.
14.
PermeTGolparianDBombek IhanM, et al.Genomic and phenotypic characterisation of invasive neonatal and colonising group B Streptococcus isolates from Slovenia, 2001-2018. BMC Infect Dis. 2020;20(1):958.
15.
VolpeJJ. Neonatal seizures: current concepts and revised classification. Pediatrics. 1989;84(3):422-428.
16.
ChequerRSTharpBRDreimaneD, et al.Prognostic value of EEG in neonatal meningitis: retrospective study of 29 infants. Pediatr Neurol. 1992;8(6):417-422.
17.
AbendNSWusthoffCJ. Neonatal seizures and status epilepticus. J Clin Neurophysiol. 2012;29(5):441-448.
18.
Amiel-TisonC. Update of the Amiel-Tison neurologic assessment for the term neonate or at 40 weeks corrected age. Pediatr Neurol. 2002;27(3):196-212.
19.
GosselinJGahaganSAmiel-TisonC. The Amiel-Tison neurological assessment at term: conceptual and methodological continuity in the course of follow-up. Ment Retard Dev Disabil Res Rev. 2005;11(1):34-51.
20.
SchragSJZywickiSFarleyMM, et al.Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342(1):15-20.
21.
PharesCRLynfieldRFarleyMM, et al.Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056-2065.
22.
FlueggeKSiedlerAHeinrichB, et al.Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics. 2006;117(6):e1139-e1145.
23.
StollBJHansenNISanchezPJ, et al.Early onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817-826.
24.
HolmesGLLombrosoCT. Prognostic value of background patterns in the neonatal EEG. J Clin Neurophysiol. 1993;10(3):323-352.
25.
TsuchidaTN. EEG background patterns and prognostication of neonatal encephalopathy in the era of hypothermia. J Clin Neurophysiol. 2013;30(2):122-125.
26.
TopjianAASánchezSMShultsJ, et al.Early EEG background features predict outcomes in children resuscitated from cardiac arrest. Pediatr Crit Care Med. 2016;17(6):547-557.
27.
KlingerGChinCNOtsuboH, et al.Prognostic value of EEG in neonatal bacterial meningitis. Pediatr Neurol. 2001;24(1):28-31.
28.
MillichapJG. Prognostic value of EEG in neonatal meningitis. Pediatr Neurol Briefs. 2001;15(3):18.
29.
TibussekDSinclairAYauI, et al.Late-onset group B streptococcal meningitis has cerebrovascular complications. J Pediatr. 2015;166(5):1187-92.e1.
30.
ChuSMHsuJFLeeCW, et al.Neurological complications after neonatal bacteremia: the clinical characteristics, risk factors, and outcomes. PLoS One. 2014;9(11):e105294.
31.
Kamga HBChateu. Neuroimaging complication of neonatal meningitis in full-term and near-term newborns: a retrospective study of one center. Glob Pediatr Health. 2016;3:2333794x16681673.
32.
HernandezMISandovalCCTapiaJL, et al.Stroke patterns in neonatal group B streptococcal meningitis. Pediatr Neurol. 2011;44(4):282-288.
33.
ConiEMarcialisMAPintusMC, et al.Group B streptococcal meningitis: a description of six case reports. Int J Clin Pediatr. 2015;4(1):127-136.
34.
LerouxBGN’Guyen The TichSBrangerB, et al.Neurological assessment of preterm infants for predicting neuromotor status at 2 years: results from the LIFT cohort. BMJ Open. 2013;3(2):e002431.
35.
SimardMNLambertJLachanceC, et al.Prediction of developmental performance in preterm infants at two years of corrected age: contribution of the neurological assessment at term age. Early Hum Dev. 2011;87(12):799-804.
36.
Paro-PanjanDNeubauerDKodricJBratanicB. Amiel-Tison neurological assessment at term age: clinical application, correlation with other methods, and outcome at 12 to 15 months. Dev Med Child Neurol. 2005;47(1):19-26.
37.
Da CunhaVDaviesMRDouarrePE, et al.Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nat Commun. 2014;5:4544.
38.
BekkerVBijlsmaMWvan de BeekD, et al.Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis. 2014;14(11):1083-1089.
39.
JonesNOliverKABarryJ, et al.Enhanced invasiveness of bovine-derived neonatal sequence type 17 group B Streptococcus is independent of capsular serotype. Clin Infect Dis. 2006;42(7):915-924.
40.
LuanSLGranlundMSellinM, et al.Multilocus sequence typing of Swedish invasive group B Streptococcus isolates indicates a neonatally associated genetic lineage and capsule switching. J Clin Microbiol. 2005;43(8):3727-3733.
41.
BellaisSSixAFouetA, et al.Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development. J Infect Dis. 2012;206(11):1745-1752.
